reports
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
KPN ROYAL KPN NV
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Konrad Zomer
PUB PUBLICIS GROUPE SA
BVI BUREAU VERITAS SA
EN BOUYGUES SA
DEMANT DEMANT A/S
WKL WOLTERS KLUWER NV
ITRK INTERTEK GROUP PLC
VNA VONOVIA SE
GRF GRIFOLS S.A. CLASS A
FRE FRESENIUS SE & CO. KGAA
NEM NEMETSCHEK SE
EVK EVONIK INDUSTRIES AG
RACE FERRARI NV
GRF.P GRIFOLS S.A. PREF CLASS B
AD KONINKLIJKE AHOLD DELHAIZE N.V.
BP. BP P.L.C.
BIM BIOMERIEUX SA
SHL SIEMENS HEALTHINEERS AG
CCEP COCA-COLA EUROPEAN PARTNERS PLC
NEXI NEXI S.P.A.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
SGSN SGS SA
NOVO B NOVO NORDISK A/S
QGEN QIAGEN N.V.
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Oncopeptides AB: 2 directors
A director at Oncopeptides AB bought 56,820 shares at 4.400SEK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- ABGSC Healthcare Research
- Morten Larsen
- Oliver Metzger
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Alexander Krämer
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.